Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

A Very Important Change Is Coming for Airplane Bathrooms

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/g4fqkbuzqjA The Department of Transportation (DOT) is making larger single-aisle airplanes more accessible by requiring accessible lavatories for people with disabilities. While this rule will be implemented over the coming years, it is a monumental achievement for the disability civil rights movement. Under previous standards, people who use wheelchairs have no way to access the restroom on single-aisle aircraft. They are forced them to dehydrate themselves, or even soil themselves, before flights – causing major bodily harm! Over the past 75 years, Paralyzed Veterans of America (PVA) has led the fight for accessibility — and air travel is no different. PVA helped pass the landmark legislation to first make air travel accessible over 35 years ago, and they played an integral role in securing accessible airplane lavatories. They continue to advocate for additional reforms that will ensure a safe, dignified air travel experience for people with disabilities. So, what does this new rule mean for the future of accessible air travel? And what else is needed to make the air travel experience fully accessible for people with disabilities? Now is an opportunity for your audience to learn more about the new rule and the ways Paralyzed Veterans of America (PVA) has helped secure this monumental achievement, and how they continue to advocate for other meaningful reforms related to the upcoming renewal of the Federal Aviation Administration. A nationwide media tour was conducted featuring Chief Policy Officer at Paralyzed Veterans of America, Heather Ansley discussing the new lavatory rule and additional reforms that must be made to make air travel fully accessible through the reauthorization of the FAA. Additional topics that were discussed included: What the new Department of Transportation rules will do. What this means for the disability community. Why this DOT rule was desperately needed. The reasons why air travel is so far behind basic standards. What else needs to be done to ensure air travel is accessible. PVA remains on the forefront of the disability civil rights movement – fighting for stronger ADA enforcement, expanding support for home-based care, and more. To join PVA’s fight for greater enforcement of the ADA, visit PVA.org/ADA, or for air travel, visit PVA.org/AirTravel. About Paralyzed Veterans of America Paralyzed Veterans of America is a 501(c)(3) non-profit and the only congressionally chartered veterans service organization dedicated solely for the benefit and representation of veterans with spinal cord injury or diseases. The organization ensures veterans receive the benefits earned through service to our nation; monitors their care in VA spinal cord injury units; and funds research and education in the search for a cure and improved care for individuals with paralysis. As a life-long partner and advocate for veterans and all people with disabilities, PVA also develops training and career services, works to ensure accessibility in public buildings and spaces, and provides health and rehabilitation opportunities through sports and recreation. With more than 70 offices and 33 chapters, Paralyzed Veterans of America serves veterans, their families, and their caregivers in all 50 states, the District of Columbia, and Puerto Rico. Learn more at PVA.org. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 25, 2023 10:40 AM Eastern Daylight Time

Video

Oxford Cannabinoid Technologies reports no adverse events in OCT461201 trial

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) chief executive Clarissa Sowemimo-Coker speaks to Thomas Warner from Proactive London after the pharmaceutical group announced it has successfully administered the final dose of its lead drug candidate, OCT461201, as part of its phase I clinical trial. Sowemimo-Coker says that no adverse events were reported during the trial, which began in late July. While awaiting the final report, the company remains optimistic about the results. She briefly touches upon the potential move into phase two studies for the compound, saying that external advisor Dr William Paul Farquhar-Smith and Chief Medical Officer Dr. Tim Corn are actively planning these next steps. Additionally, the company's AGM is slated for Thursday, presenting another opportunity for shareholder engagement. Oxford Cannabinoid Technologies is a pharmaceutical group developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the U$ multi-billion pain market. The group is developing OCT461201 as a potential treatment for chemotherapy-induced peripheral neuralgia (CIPN). Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 25, 2023 06:00 AM Eastern Daylight Time

Video

News Release

Lophos Pharmaceuticals announces company is now trading on the CSE under the ticker MESC

Lophos Pharmaceuticals

Lophos Pharmaceuticals CEO Claire Stawnyczy joined Steve Darling from Proactive to share the news that the company which specializes in the cultivation, research, and sale of Lophophora williamsii or peyote cactus has achieved significant milestones. Lophos Pharma has commenced trading on the Canadian Securities Exchange (CSE) under the ticker symbol "MESC." This development marks a significant step for the company in terms of visibility and accessibility to investors. The company has successfully obtained a Controlled Substances Dealers License from Health Canada. This license empowers Lophos Pharma to engage in various activities related to controlled substances, including possession, production, sale/provision, sending, transportation, and delivery. The controlled substances covered by this license include mescaline, psilocin, and psilocybin. Lophos Pharma has entered into a strategic partnership with KGK Science to explore potential pathways to market sustainably grown, peyote-derived natural health products. While peyote itself is legally recognized in Canada, mescaline—the psychoactive compound derived from the peyote cactus—remains classified as a Schedule 3 controlled substance. These developments underscore Lophos Pharma's commitment to advancing its unique position in the emerging market of natural health products derived from peyote. The company's ability to obtain a Controlled Substances Dealers License is particularly noteworthy, as it positions Lophos Pharma to engage in research, production, and distribution of controlled substances in compliance with Canadian regulations. As Lophos Pharma continues its work in researching and developing peyote-derived products, its collaboration with KGK Science represents a key partnership to explore the potential for sustainable and legal market opportunities in this evolving sector. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

September 22, 2023 01:34 PM Eastern Daylight Time

Video

Comcast Donates Free WiFi Access to Four Nonprofits in the Twin Cities to Help Increase Digital Opportunities in the Region

Comcast Twin Cities

Comcast today announced the opening of four new Lift Zones in the Twin Cities to provide free WiFi access to families across the area. Furthering the company’s deep and longstanding commitment to advancing equity and opportunity, our new Lift Zones at the International Institute, Every Third Saturday, Al Maa’uun, and GMCC will support digital access and adoption through tech training and career building. The new Lift Zone at International Institute will also receive 250 new laptops and two privacy pods, which will be used for virtual job interviews and telehealth appointments, as needed by clients. Comcast’s Lift Zones program provides free WiFi, powered by Comcast Business, to enable students, seniors, families, and community members to get online and fully participate in the digital economy. With these four new locations, Comcast now offers over 115 Lift Zones throughout the Twin Cities. Comcast’s investments in the four partner organizations will help increase college and career readiness, especially among underserved youth; connect workers to opportunities; provide upskilling for adult learners and those already in the workforce; and close the skills – particularly digital skills – gap. “The tasks of starting a new life in a new country can be overwhelming for refugees and immigrants when they arrive. Digital literacy and lack of reliable internet access can get in the way of applying for work, participating in classes or accessing community services,” said Jane Graupman, Executive Director, International Institute of Minnesota. “Thanks to Comcast and this Lift Zone partnership, we can make this time a little easier for New Americans who contribute so much to our community.” “Helping to close the digital divide and address digital equity remain top priorities here in the Twin Cities,” said Makram El-Amin, Executive Director from Al Maa’uun. “Our city and our region have become even more dependent on broadband to learn, find work and healthcare services and so many other aspects of our daily life. Comcast’s new Lift Zones will create endless opportunities for so many individuals, families, and seniors in our community.” “We’re proud to partner with these four wonderful organizations to launch new Lift Zones to advance digital equity and workforce readiness in our most vulnerable neighborhoods,” said Kalyn Hove, Regional Senior Vice President, Comcast Midwest. “Our continued partnership with our community partners will equip individuals, families and seniors with the tools, skills and resources they need to achieve their goals.” “Helping our communities achieve digital equity is in our DNA at Comcast,” said Broderick Johnson, EVP, Public Policy, and EVP, Digital Equity, Comcast Corporation. “We’re thrilled to partner with the International Institute, Every Third Saturday, Al Maa’uun, and GMCC on our next installation of Lift Zones in the Twin Cities and to work with partners who share our same goals of closing the digital divide.” Today’s announcement is part of Project UP, Comcast’s $1 billion commitment to reach millions of people with the tools, resources, and skills needed to succeed in a digital world. Comcast’s Lift Zones complement Internet Essentials, which since 2011, has helped connect more than 10 million low-income people to the Internet at home. In Minnesota, the program has connected more than 416,000 Minnesotans. Comcast also participates in the Affordable Connectivity Program (ACP), which provides qualifying households with a $30 per month credit, or $75 per month on Tribal lands, toward their Internet and mobile services. New and existing Xfinity Internet or Internet Essentials customers can learn more about the program and sign up by visiting: https://www.xfinity.com/learn/internet-service/acp/free-internet. About Comcast Corporation Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company. From the connectivity and platforms we provide, to the content and experiences we create, our businesses reach hundreds of millions of customers, viewers, and guests worldwide. We deliver world-class broadband, wireless, and video through Xfinity, Comcast Business, and Sky; produce, distribute, and stream leading entertainment, sports, and news through brands including NBC, Telemundo, Universal, Peacock, and Sky; and bring incredible theme parks and attractions to life through Universal Destinations & Experiences. Visit www.comcastcorporation.com for more information. Contact Details Comcast Corporation Jill Hornbacher +1 651-425-1695 Jill_Hornbacher@comcast.com Company Website https://midwest.comcast.com

September 21, 2023 10:00 AM Central Daylight Time

Synairgen looking beyond COVID in fight against respiratory illness

Synairgen PLC

Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden speaks to Thomas Warner from Proactive London about the company's ongoing efforts to develop what he describes as a "drug to help patients handle respiratory viruses." He explains that work on the drug long predates the COVID pandemic and has intensified since, but is careful to emphasise that the intention of Synairgen is to develop a respiratory drug that can be of use to patients with other respiratory conditions as well. He notes the importance of looking beyond COVID-19, given the unpredictability of its media presence and its potential long-term existence alongside other viruses. Marsden discusses their past Sprinter trial and the need for targeted future clinical trials. Utilising technologies and data that emerged during the pandemic, Synairgen plans to identify patients most likely to deteriorate due to the virus. This strategic approach aims to conduct faster trials with a higher chance of success. Marsden concluded that as they refine patient selection for upcoming trials, they'll announce results and commence the next clinical trial phase. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 21, 2023 08:40 AM Eastern Daylight Time

Video

Genflow Biosciences reports positive news from Belgium

Genflow Biosciences PLC

Genflow Biosciences PLC (LSE:GENF, OTC:GENFF) CEO Dr. Eric Leire speaks to Thomas Warner from Proactive after the longevity-focused UK based biotech company released a company update highlighting a successful first regulatory interaction with the Federal Agency for Medicines and Health Products (FAHMP) in Belgium. Dr Leire explains that the news helps pave the way for clinical trials and was particularly noteworthy because of the agency's recommendation to commence directly with NASH (Non-Alcoholic Steatohepatitis) patients, bypassing the traditional phases. He expects the move to accelerate the proof of concept process and boost the company's valuation. Additionally, a strategic restructuring is underway, aimed at enhancing eligibility for grants, a crucial aspect in mitigating financial risk for early-stage biotech ventures. Dr Leire explains that the move aligns with Genflow's strategy of minimising reliance on venture capital funding and focusing instead on attracting non-dilutive grants. He also draws attention to planned FDA interaction and promising in vivo studies. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 20, 2023 07:10 AM Eastern Daylight Time

Video

BiVictriX Therapeutics "looking really healthy" after positive first half

BiVictriX Therapeutics PLC

BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) founder and CEO Tiffany Thorn speaks to Thomas Warner from Proactive after the UK-based drug discovery and development company released its interim results for the six months to 30 June 2023. Thorn gives her take on how the business performed during the reporting period, highlighting the nomination of a clinical candidate for the lead programme, BVX001 as well as progress on BVX002 and BVX003. BiVictriX also bolstered its financial position with a successful fundraise, raising over £2 million, supplemented by a £0.5 million R&D tax credit claim. Thorn emphasises the robust financial position of the company, saying that the runway "is looking really healthy... we've got sufficient funds to carry out our near-term objectives." She also mentions growth in the team itself, as it sharpens its focus on the partnering opportunities that she describes as the company's key focus. Looking ahead, the focus lies on advancing program readiness for clinical use, scaling up drug manufacturing, and forging those key business development relationships. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 20, 2023 03:00 AM Eastern Daylight Time

Video

Scancell CEO hails "exciting" high response rate to melanoma treatment

Scancell Holdings PLC

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the initial phase of the clinical stage biopharmaceutical company's Phase 2 SCOPE trial in advanced melanoma. Professor Durrant gives an overview of the findings so far, saying that in the initial 11 patients they have achieved an impressive 82% overall response rate, surpassing the anticipated 70%. This development could be crucial for metastatic melanoma patients, as previous studies reported only a 50% response rate. She adds that the potential to significantly improve outcomes is especially significant given the rising cases, particularly among young women. While further confirmation is needed in a larger cohort, the data's strength suggests promising results in the broader study. Looking ahead, the trial aims to recruit 43 patients, expecting over 27 respondents, with potential adjustments based on the remarkable initial response rate. Professor Durrant also provides an update on Modi1 vaccine and Scancell's antibody platform. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 20, 2023 03:00 AM Eastern Daylight Time

Video

News Release

Tonix Pharmaceuticals releases positive results from Proof-Of-Concept Study on TNX-102 SL

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr Seth Lederman joined Steve Darling from Proactive to share significant news regarding the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL 5.6 mg for the management of fibromyalgia-type Long COVID. Dr Lederman provided an overview of the study's topline results and the implications for future development. Dr Lederman announced that the study showed a robust effect size in improving fatigue, a key symptom of Long COVID. The results also demonstrated consistent activity trending towards improvements across secondary endpoints, including sleep quality, cognitive function, disability, and patient global impression of change. However, Dr Lederman noted that TNX-102 SL did not achieve the pre-specified primary endpoint of improving Long COVID pain intensity scores at Week 14. Despite this, the proposed mechanism of TNX-102 SL, which aims to improve sleep quality, aligns with recent announcements from the National Institutes of Health (NIH) that sleep quality is a target for future clinical trials in Long COVID. Dr Lederman highlighted that there is currently no approved drug for the treatment of Long COVID, making these findings important for potential future treatments. The company's plan is to request an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the possibility of a Phase 3 program. They intend to propose a primary outcome measure using the PROMIS Fatigue scale, which is widely recognized and validated for assessing fatigue across various conditions. Dr Lederman also told Proactive the company is committed to meeting potential increased demand for its Tosymra nasal spray 10 mg following GlaxoSmithKline’s planned discontinuation of Imitrex nasal spray 5 mg and 20 mg products after January 2024. This move by Tonix is to be ready in case of possible drug shortages for patients who suffer from migraines. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

September 19, 2023 01:54 PM Eastern Daylight Time

Video

1 ... 58 59 60 61 62 ... 258